Damy T, Garcia‐Pavia P, Hanna M, et al. - The present study was conducted to evaluate whether tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR‐CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT). Individuals were assigned randomly in a 2:1:2 ratio to tafamidis 80 mg, 20 mg, or placebo for 30 months in ATTR‐ACT. Researchers evaluated all‐cause mortality in ATTR‐ACT combined with the long‐term extension study (median follow‐up 51 months). The results exhibited that in patients with ATTR‐CM, tafamidis, both 80 and 20 mg, effectively decreased mortality and cardiovascular‐related hospitalizations. The outcomes of this study revealed that the longer‐term survival data and the lack of dose‐related safety concerns support tafamidis 80 mg as the optimal dose.